Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: Provided is a pharmaceutical composition for use in the treatment or prevention of cancer, etc. The present invention provides a pharmaceutical composition or a method for treating cancer, wherein an anti-GARP antibody and an immunomodulator are administered in combination.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: A method for the detection of impaired responsiveness of CD4+ T-cells to regulatory T-cells (Treg), Treg resistance, by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1?) in activated CD4+ T-cells, in particular in patients suffering from relapsing remitting multiple sclerosis. The invention relates to an in vitro screening method for the detection of an autoimmune disease or a condition, comprising the steps of generating a functional gene expression profile by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1?) in Treg-resistant CD4+ T-cells from patients suffering of an autoimmune disease or condition, and comparing the obtained gene expression profile with the expression profile from Treg-sensitive CD4+ T-cells from healthy controls.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

Abstract: A method for the detection of impaired responsiveness of CD4+ T-cells to regulatory T-cells (Treg), Treg resistance, by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1?) in activated CD4+ T-cells, in particular in patients suffering from relapsing remitting multiple sclerosis. The invention relates to an in vitro screening method for the detection of an autoimmune disease or a condition, comprising the steps of generating a functional gene expression profile by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1?) in Treg-resistant CD4+ T-cells from patients suffering of an autoimmune disease or condition, and comparing the obtained gene expression profile with the expression profile from Treg-sensitive CD4+ T-cells from healthy controls.

Abstract: A connector mechanism for a card, capable of being thinned, and a card adaptor having a connector mechanism for a card. A connector mechanism for a card, having an installation section (2a) in which a card (1) having external connection sections is installed and having a terminal member (9) with which the external connection sections of the card (1) can come into contact. The mechanism further has a lift-up mechanism including a projection section (2b) that once lift a front end section (1a) of the card (1) upward and then causes each of the external connection sections of the card (1) to be in contact with a corresponding one of the terminals (9a-9c) of the terminal member (9).

Abstract: [Object] To provide a low-profile card connector mechanism and a card adapter having the card connector mechanism. [Solving Means] A card connector mechanism includes a holder portion 2a for holding a card 1 having a plurality of external connection portions, and a terminal member 9 with which the external connection portions of the card 1 are contactable. The card connector mechanism further includes a lifting mechanism having protrusions 2b. The lifting mechanism temporarily lifts an anterior end 1a of the card 1 upward and then brings the external connection portions of the card 1 into contact with corresponding terminals 9a to 9c of the terminal member 9.

Abstract: Provided is a card connector including a first contact which is connected to a first card (card B), a second contact which is disposed toward an insertion port of the card from the first contact so as to be connected to a second card (card C), and a protection plate which protects the second contact from the contact with the first card. A guide piece which guides the bottom surface of the first card is formed in a housing in which the first and second cards are selectively mounted, and a support surface which is disposed in a position toward the insertion port and on the upper side from the guide piece is formed on the protection plate. The first card is inserted in a state where the leading end thereof is inclined more downward than the rear end thereof.

Abstract: Provided is a card connector including a first contact which is connected to a first card (card B), a second contact which is disposed toward an insertion port of the card from the first contact so as to be connected to a second card (card C), and a protection plate which protects the second contact from the contact with the first card. A guide piece which guides the bottom surface of the first card is formed in a housing in which the first and second cards are selectively mounted, and a support surface which is disposed in a position toward the insertion port and on the upper side from the guide piece is formed on the protection plate. The first card is inserted in a state where the leading end thereof is inclined more downward than the rear end thereof.

Abstract: A first fuel state determination section determines a fuel condition purged from a canister based on a quantity of deviations from a target air fuel ratio of the measured air-fuel-ratio. A second fuel state determination section determines a fuel condition after a purge control valve has closed. An abnormality detecting section detects an abnormalities of the second fuel state determination section. An air-fuel-ratio learning section performs air-fuel-ratio learning. An air-fuel-ratio-control section controls a fuel injection quantity based on the fuel condition. An initiation timing of the purge by a purge control valve is adjusted based on a history of an abnormality detection of the second fuel state determination section and a learning history of the air-fuel-ratio learning section. A fuel vapor treatment apparatus which can enlarge a purge amount enough is provided.

Abstract: There is provided a polypeptide that binds to syntaxin-1a and comprises the amino acid sequence shown in SEQ ID NO: 1 in the Sequence Listing, or a polypeptide having a homology of at least approximately 90% to the amino acid sequence that binds to syntaxin-1a, a partial peptide thereof, and a polynucleotide encoding any of these polypeptides or the complementary strand thereof, as well as an inhibitor, an antagonist, and an activator of physiological activity of any of the polypeptides. Further, a pharmaceutical composition that utilizes these is provided. There is also provided a method for producing the polypeptides or the peptide by genetic engineering techniques, a method for identifying the inhibitor, antagonist, or activator, and a method and a kit for diagnosing a disease with which the polypeptides are associated.